source
- Moderna and Merck’s individualized cancer vaccine shows promising melanoma results but shares tumble after ESMO presentationInvestors closely watched the European Society for Medical Oncology (ESMO) meeting for updates on an individualized neoantigen cancer vaccine being co‑developed by Moderna and Merck. The therapy, c…
- Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressureLilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted…